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Valosin-containing protein regulates the
proteasome-mediated degradation of
DNA-PKcs in glioma cells
N Jiang1,2,6, Y Shen3,6, X Fei1, K Sheng4, P Sun3, Y Qiu1, J Larner5, L Cao1, X Kong*,1 and J Mi*,3,5
DNA-dependent protein kinase (DNA-PK) has an important role in the repair of DNA damage and regulates the radiation
sensitivity of glioblastoma cells. The VCP (valosine-containing protein), a chaperone protein that regulates ubiquitin-dependent
protein degradation, is phosphorylated by DNA-PK and recruited to DNA double-strand break sites to regulate DNA damage repair.
However, it is not clear whether VCP is involved in DNA-PKcs (DNA-PK catalytic subunit) degradation or whether it regulates the
radiosensitivity of glioblastoma. Our data demonstrated that DNA-PKcs was ubiquitinated and bound to VCP. VCP knockdown
resulted in the accumulation of the DNA-PKcs protein in glioblastoma cells, and the proteasome inhibitor MG132 synergised this
increase. As expected, this increase promoted the efficiency of DNA repair in several glioblastoma cell lines; in turn, this enhanced
activity decreased the radiation sensitivity and prolonged the survival fraction of glioblastoma cells in vitro. Moreover, the VCP
knockdown in glioblastoma cells reduced the survival time of the xenografted mice with radiation treatment relative to the control
xenografted glioblastomamice. In addition, the VCP protein was also downregulated inB25% of GBM tissues from patients (WHO,
grade IV astrocytoma), and the VCP protein level was correlated with patient survival (R2¼ 0.5222, Po0.05). These findings
demonstrated that VCP regulates DNA-PKcs degradation and increases the sensitivity of GBM cells to radiation.
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Valosin-containing protein (VCP), is a member of the AAA class
of ATPases and associated with diverse cellular activities.1,2
VCP is an abundant protein in the cytosol and nucleus,3,4 and
physiologically exists as a homohexamer. Most, if not all,
hexamers make further complexes with other adaptor proteins,
such as p47 or Ufd1–Npl4,5,6 and escort ubiquitin–protein
conjugates to the proteasome through protein–protein interac-
tions in order to prevent the formation of excessive multiubiquitin
chain sizes.2 Moreover, recent data show that VCP also
regulates protein ubiquitination by activating a deubiquitinating
enzyme, Ataxin-3.7 It is believed that VCP is directed to relevant
cellular processes through differential binding to specific
adaptor proteins.8 Each VCP protomer is composed of four
regions: the N-terminal, two ATPase (D1 and D2) and the
C-terminal regions.1,9 The N-terminal region possesses binding
activities to the adaptor proteins as well as ubiquitinated
proteins.1 VCP has been proposed to perform many physiolo-
gical cellular functions, such as the protein degradation
mediated by the ubiquitin-proteasome system.5,10–14
Interestingly, VCP has also been reported to be recruited to
DNA double-strand break (DSBs) sites by interacting with
BRCA1, p53 and RAD51, and it might regulate DNA damage
repair.4,15,16 A recent study has revealed that VCP is a novel
substrate of DNA-dependent protein kinase (DNA-PK) and
other PIKK family members.17 In response to DNA damage,
VCP is phosphorylated at Ser 784 within its COOH terminus,
a region shown to target VCP to specific intracellular
compartments; VCP is then accumulated at the sites of DSBs
with the ubiquitin ligase RNF8, ubiquitin adaptor UFD1–NPL4
and Lys-48-linked ubiquitin (K48-Ub) chains.16 The DNA
damage-induced phosphorylation of VCP and its recruitment
to DSBs sites suggest a role for VCP in DNA repair.
The DNA-PK is a DNA-activated serine/threonine protein
kinase conserved in vertebrates.18 DNA-PK is composed of a
catalytic subunit (DNA-PKcs) and one Ku heterodimer,19 and
it is ubiquitously expressed in almost all mammalian cells.
Numerous studies have shown that DNA-PK has essential
roles in the repair of DSBs, especially in non-homologous end
joining (NHEJ). Moreover, DNA-PK not only has a critical role
in the DNA damage repair pathway, but it is also involved in
other important physiological or pathological processes,20
such as radiation sensitivity, inflammatory responses and
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metabolic gene expression.21–23 However, it is still unknown
how DNA-PK protein degradation is regulated and whether
VCP affects the radiation sensitivity.
In this study, we investigated the association of VCP with
DNA-PKcs and the effect of the regulation of VCP on the
radiosensitivity of glioblastoma cells. Our data demonstrated
that DNA-PKcs was ubiquitinated and bound to VCP; the VCP
knockdown resulted in the accumulation of DNA-PKcs protein in
glioblastoma cells and increased DNA-PK activity, which
eventually increased the survival fraction of GBM cells post-IR
and shortened the survival time of orthotopic xenografted mice.
Results
VCP is associated with DNA-PK and the D1 domain of
VCP is essential for this binding. According to bioinfor-
matic analysis, the DNA-PKcs protein contains a
VCP-interacting motif (VIM), which is conserved in mammals
such as humans, monkeys, cows and wolves (Figure 1a).
To determine whether VCP is associated with DNA-PK,
co-immunoprecipitation (co-IP) was performed using the
DNA-PKcs antibody in several glioblastoma cell lines;
the M059J cell is DNA-PKcs-deficient, and was used as a
negative control. Western blots following co-IP showed that
VCP is pulled down with DNA-PKcs (Figure 1b); moreover, in
agreement with our previous study,24 the more sensitive the
cell is, the more VCP associates with DNA-PK, indicating that
VCP may be related to radiation resistance. However,
radiation itself does not significantly affect the binding of
VCP with DNA-PKcs (data not show).
To further determine which domain of VCP is essential for
this binding, the plasmids containing different VCP domains
were separately transfected into 293T cells. Including an
empty vector, seven plasmids, as outlined in the schematic
drawing in Figure 1c, were generously provided by
Dr. Ueffing.25 Two days after transfection, whole lysates from
293T cells were subjected to western blot analysis, and 1 mg
of total protein was used for IP against the flag antibody.
Western blots following IP showed that the full-length, the
isolated N domain and the isolated D1 domain, but not the
D2 domain, can directly bind to DNA-PK, and only the
ND1 domain of the fusion proteins can bind with DNA-PK. The
ND2 fusion proteins have no detectable binding with DNA-PK,
and the D1D2 fusion protein also weakens the binding affinity
of the D1 domain to DNA-PK. These observations suggest
that the D2 domain has a negative influence on the binding
of DNA-PK with VCP, which may be mediated by
multiple mechanisms, including mutually exclusive binding
or conformational changes.
In addition, the full-length VCP-immunoprecipitated
DNA-PKcs protein was less than that immunoprecipitated by
the isolated N domain or D1 domain; moreover, the total DNA-
PKcs protein in the full-length VCP-transfected 293T cells
also decreased. These observations suggest that the reduced
signal most likely resulted from the decreased total DNA-PKcs
protein, and that the overexpression of VCP might have
caused the degradation of DNA-PKcs. The western blot
for whole-cell lysates showed that all truncates containing
VCP domains were equally overexpressed (bottom panel
of Figure 1d).
Figure 1 VCP was associated with DNA-PK. (a) The VIM and the protein sequence alignment among humans, monkeys, cows and wolves. (b) The VCP was pulled down
by DNA-PKcs IP in different GBM cell lines (WL: whole-cell lysates). DNA-PKcs-deficient M059J cells were considered as negative controls. (c) The schematic drawing of the
truncated VCP protein. All truncates were tagged with the Flag epitope (FL: full-length). (d) The plasmids expressing different domains of VCP were separately transfected into
293T cells (con: empty vector), and flag immunmoprecipitation was performed. Both DNA-PKcs and flag were detected in whole-cell lysates (bottom panels, shown as WL) or
flag IPs (top panels)
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DNA-PKcs degradation is ubiquitin-proteasome-dependent
and regulated by VCP. To determine whether DNA-PK
protein degradation is dependent on proteasomes and
whether VCP regulates DNA-PK degradation, VCP was
knocked down by lentivirus-mediated shRNA (this shRNA
was verified by the other group26) in U251 cells or U87 cells.
Western blots showed that DNA-PKcs was upregulated
in VCP-knockdown cells, while the overexpression of
VCP reduced the amount of DNA-PKcs (Figure 2a), which
indicates that VCP regulates the DNA-PKcs protein level.
Regarding of the function of VCP, VCP might affect DNA-
PKcs degradation. To exclude the possibility that VCP
regulates the transcription of DNA-PKcs, quantitative PCR
(q-PCR) was performed in order to assess the level of
DNA-PKcs mRNA. The level of DNA-Pkcs mRNA was
detected in VCP-knockdown cells, control cells and parental
cells (Figure 2b). As expected, there was no significant
difference in DNA-PKcs mRNA levels among VCP knock-
down U87, control U87 or parental U87 cells, which suggests
that VCP might regulate DNA-PKcs degradation instead of
modulating its transcription.
Because the VCP-mediated protein degradation is
ubiquitin-proteasome-dependent, to determine whether
DNA-PKcs is ubiquitinated, DNA-PKcs was purified via IP
and followed by ubiquitin detection. The western blot showed
that the ubiquitin signal only appeared in the DNA-PKcs-
proficient U251 cells at the size of DNA-PKcs, but not in the
DNA-PKcs-deficient M059J cells or nonspecific IgG lane,
which indicates that the DNA-PKcs was ubiquitinated
(Figure 2c). To further identify whether DNA-PKcs degrada-
tion is dependent of the proteasome system, U251 cells were
treated with the proteasome inhibitor MG132 (125 nM) and
harvested at the indicated time points (0, 12, 24, 48, 72 h)
based on the half-life of the DNA-PKcs protein.
The western blot data showed that the DNA-PKcs protein
level was significantly increased 24 h after MG132 treatment;
the longer the treatment lasted, the more the DNA-PKcs
accumulated (Figure 2c), which indicates that the DNA-PKcs
degradation was dependent on the ubiquitin-proteasome
system, although the typical smeared bands were not
seen, perhaps due to the high-molecular weight of DNA-PKcs
(460 KD). To determine whether VCP knockdown has
synergistic effects on DNA-PKcs accumulation with protea-
some inhibition, the control and the VCP-knockdown U251
cells were treated with MG132 for the indicated time (0, 3, 6,
12 h). The immunoblots showed that the DNA-PKcs was
dramatically increased in VCP-knockdown U251 cells 3 h after
MG132 treatment (Figure 2d). Moreover, to exclude the
possibility that this increase was dependent on lysosomes,
VCP-knocked down U251 cells were treated with the
lysosome inhibitor chloroquine at the indicated concentration.
The western blot showed that chloroquine had no effects
on DNA-PKcs accumulation, even 6 h after treatment; in
contrast, chloroquine decreased the protein levels of
both DNA-PKcs and VCP (Figure 2e). In brief, our data
demonstrated that DNA-PKcs was ubiquitinated and
that VCP regulated DNA-PKcs degradation through the
ubiquitin-proteasome system.
Knockdown of VCP enhances the DNA-PK activity
and increases the efficiency of DNA damage repair. To
determine whether VCP regulates DNA-PK activity as well as
DNA-PKcs protein levels, the endogenous DNA-PK activity
was directly assessed via in vitro kinase assay, and indirectly
measured through the phosphorylation of endogenous RPA32
(the 32-kDa subunit of replication protein A). Although RPA32
is differentially phosphorylated by three PI3Ks (ataxia
telangiectasia mutated protein, ATM, ATM-Rad3-related
protein and DNA-PK) in response to different DNA damaging
agents, DNA-PK is the primary kinase responsible for
camptothecin (CPT)-induced RPA32 phosphorylation;27–29,24
thus, CPT-induced RPA32 phosphorylation is another indica-
tor of DNA-PK activity.
In the in vitro kinase assay, our data showed that DNA-PK
was activated by ionising radiation and that VCP knockdown
enhanced this activation, which was one and a half times more
than that in control cells, as shown in the first graphic
of Figure 3a. In response to CPT treatment, the Ser 4/8
phosphorylation of RPA32 was observed as the appearance
of a band of reduced mobility relative to the parent
RPA32 band, and this shifted band was confirmed by the
phosphorylation-specific antibody. This CPT-induced RPA32
phosphorylation in parental U251 cells, U251 cells with VCP
Figure 2 VCP regulated DNA-PKcs degradation and this degradation was
ubiquitin-proteasome-dependent. (a) U251 or U87 cells were infected with VCP
shRNA lentiviruses or VCP expression lentiviruses. Immunoblots were performed
against whole-cell lysates (Par: parent U251 cells; Consi: nonspecific RNA; VCPsi:
VCP-specific siRNA). (b) The real-time PCR was performed using DNA-PKcs-
specific primer in U251 cells infected with different lentiviruses (Par: parent U251
cells); DNA-PKcs mRNA levels are relative to GAPDH. (c) Top panel: DNA-PKcs
was immunoprecipitated, and both DNA-PKcs and ubiquitin were detected on the
same membrane (WL: whole-cell lysates). Bottom panel: DNA-PKcs was detected
in parent U251 cells treated with MG132 (125 nM) for the indicated dose. (d) Parent
U251 cells or U251 cells infected with different lentiviruses were treated with the
proteasome inhibitor MG132 (50 mM), and the DNA-PKcs protein was detected at
the indicated time points. (e) Parent U251 cells or cells infected with different
lentiviruses were treated with the lysosome inhibitor chloroform at the indicated
concentrations, and the DNA-PKcs protein was detected 12 h after treatment
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knockdown or control siRNA (Figure 3a) were analysed by
densitometry using ImageJ software (NIH, USA). The ratio of
phosphorylated RPA32 (top panel) to total RPA32 (two bands
in the second panel), which represents DNA-PK activity, was
calculated in each lane. The ratio of p-RPA32 in the
VCP-knockdown U251 cells was two times more than that in
the control U251, as shown in the last graphic of Figure 3a.
The total RPA32 was increased in the VCP-knockdown cells,
but the cause of this is unknown.
Moreover, the COMET assay and g–H2AX detection, which
represent the DNA damage level in each cell, were performed
in order to assess the efficiency of DNA damage repair. In the
COMET assay, the cells were irradiated with 10 Gy radiation
on ice. Treated cells were harvested and recovered for the
indicated time (30, 180, 360 min), and the cells were subjected
to single-cell electrophoresis under neutral conditions. Each
time, 200 cells for each group were measured at 200 times
magnification. The tail lengths were measured and Olive tail
moment (OTM) values were calculated using CASP software
based on the formula: OTM¼ tail DNA %  (tail mean head
mean). After 30 min, there was no significant difference
between the control U251 cells and the VCP-knockdown
cells. However, after 3 or 6 h of recovery, the tail lengths or the
OTM values were obviously longer or greater in control U251
Figure 3 VCP knockdown increased DNA-PK activity and promoted the efficiency of DNA damage repair. (a) Parent U87 cells or cells infected with control lentiviruses or
VCP shRNA lentiviruses were treated with 5 Gy of radiation or camptothecin (20 mM). The in vitro kinase assay was performed on cells treated with radiation. Cells treated with
CPT were subjected to immunoblot, and ser 4/8 phosphorylation of RPA32 was detected by densitometry analysis 2 h after the treatment (the columns present the
mean±S.D., three independent experiments were performed). The ratio of phosphor-RPA32 to total RPA32 was calculated, and the value was normalised to the b-actin
density. (b) U87 cells infected with control lentiviruses or VCP shRNA lentiviruses were treated with 5 Gy of radiation; the cells were harvested at indicated time points for
comet assay, and 100 cells in each group were measured for the value of OTM and tail length. (c) U87 cells with control lentiviruses or VCP shRNA lentiviruses were
immunostained with g-H2AX after receiving 2 Gy radiation; 100 cells were counted, and the graphic presents the average number of foci per cell at the indicated time points
(red: g-H2AX; blue: DAPI). (Par: parent U87 cells; Consi: nonspecific RNA; VCPsi: VCP-specific siRNA)
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cells compared with that in the VCP-knockdown U251 cells
(Po0.05), as shown in Figure 3b, which suggests that VCP
knockdown promoted DNA repair efficiency.
Furthermore, another DNA damage marker, g-H2AX foci,
was also counted in the U251 cells treated with 2 Gy of
radiation (the data with other doses of radiation are not
shown). One hour after radiation, massive g-H2AX foci were
observed in both the U251 control cells and VCP-knockdown
cells, and almost every single cell contained numerous foci
(red dots). Six hours after radiation, most control cells had no
dramatic changes in g-H2AX staining, while the foci in half of
the VCP-knockdown cells had disappeared (Po0.01)
(Figure 3c). Eventually, both control and VCP-knockdown
cells had no foci detectable after 24 h of recovery. All these
observations demonstrate that VCP knockdown enhances the
DNA-PK activity and increases the efficiency of DNA damage
repair.
VCP knockdown increases the survival fraction of GBM
cells after radiation treatment and shortens the survival
of orthotopic xenografted mice. To determine whether
VCP regulates the radiation sensitivity of GBM cells, an
in vitro clonogenic assay and in vivo orthotopic mouse model
were used in this study. In the clonogenic assay, signalised
VCP-knockdown U87 cells or U251 cells were seeded in
100-mm dishes (400 cells each); the cells were irradiated at
the indicated dose and then were cultured for 2 weeks.
The colonies containing 50 cells or more were counted. VCP
knockdown increased the survival fraction in both U251 cells
and U87 cells. After 2 Gy of radiation, VCP knockdown
promoted the survival of U251 cells from 29.3 to 51.3%
(Po0.01) and the survival of U87 cells from 34.9 to 62.3%
(Po0.01) (Figure 4a). U87 cells were more resistant to
radiation than U251 cells, which was consistent with our
previous study.24 There were no significant effects on
survival between the control and parental U251 or U87 cells.
To further confirm whether VCP knockdown increased
radiation resistance is dependent on DNA-PK, a pair
of DNA-PKcs-proficient (M059K) and deficient-(M059J)
GBM cells were used in this study. Our data showed that
VCP knockdown significantly enhanced the survival of
DNA-PK-proficient M059K cells, but not DNA-PK-deficient
M059J cells, demonstrating that VCP knockdown-produced
radiation resistance is DNA-PK-dependent.
In the orthotopic mouse model, U87 cells infected with
empty viruses served as controls, and 48 mice in total were
injected. Nine days after the injection, mice bearing tumours
(39 mice) were randomly divided into two groups according to
the MRI imaging, including IR and non-IR irradiation. Each
group contained control and knockdown subgroups (10 mice
in each subgroup). The 6 Gy of total radiation were adminis-
tered three times over 1 week; the schedule is described in the
Materials and Methods section. The survival time of each
mouse was recorded, and all survival times in each group
were analysed using the Kaplan–Meier method. Our data
showed that the radiation treatment prolonged the mice’s
survival time in all groups. With radiation treatment, the mice
in the VCP-knockdown group survived for a shorter time
(38.4 days, median survival time) than the mice in control
groups, whose survival time was 53.8 days (Figure 4b).
Without radiation treatment, the survival time in the VCP-
knockdown group was slightly shorter than that in the control
group. The radiation enhancement ratio of survival time in the
VCP-knockdown group was 2.69%, much lower than that in
the control group (27.1%); the difference was statistically
significant (Po0.001) (Figure 4b).
On the basis of the MRI image of tumours at the 9th day
after intracranial injection, the tumour size in each group
differed, but not significantly, as seen in the representative
pictures in the middle graphic of Figure 4c. As we expected,
the tumour sizes in the VCP-knockdown group at the 29th day
were obviously larger than that in the same mouse at the 9th
day, as shown in the representative images in the right column
of middle graphic (Figure 4c). The average tumour volumes in
each group were calculated and are shown in Figure 4c. The
tumour sizes shrunk more (28.9%) in the control group than in
the VCP-knockdown group (6.3%) after radiation treatment.
The representative fluorescence immunostaining pictures of
VCP protein levels in the xenografted GBM are shown in
Figure 4c.
To further investigate VCP expression and its effects on the
radiation sensitivity of GBM, the VCP protein expression in
GBM sections from patients (grade IV astrocytoma) were
semiquantified with Tissue IA quantitative analysis software
(Leica, Solms, Germany), and the correlation with survival
time was analysed. All digital images were normalised to the
negative control. Scores less than 10% were considered to be
‘ ’; the scores greater than 10% and less than 25% were
considered to be ‘þ ’; and scores more than 25% were
considered to be ‘þ þ ’. The data showed that VCP was
differentially expressed in the GBM tissue and that the VCP
expression level was positively correlated with patients’
survival time (R2¼ 0.5222, Po0.05). Patients bearing high
levels of VCP would survive longer with radiation treatment
(Figure 4d).
The representative pictures are shown in Figure 4e. This
observation was consistent with our animal data.
Discussion
We first found that the DNA-PKcs is ubiquitinated and bound
to VCP; the treatment with proteasome inhibitor (MG132), but
not lysosome inhibitor (chloroquine), increased the protein
level of DNA-PKcs; the VCP knockdown had a synergistic
effect with the MG132 treatment on DNA-PKcs protein
accumulation. As a carrier, VCP binds to polyubiquitinated
protein and delivers it to the proteasome system for
degradation; thus, either proteasome inhibition or VCP
knockdown increased the DNA-PKcs protein level, and the
combination of both synergistically increased the DNA-PKcs
protein level. These observations demonstrated that VCP
regulates DNA-Pkcs protein degradation, which is ubiquitin-
proteasome-dependent. Interestingly, MG132 treatment also
increased the level of the VCP protein itself, which suggests
that the degradation of VCP is also regulated by the ubiquitin-
proteasome system. Moreover, chloroquine treatment
unexpectedly decreased the protein level of both DNA-PKcs
and VCP in glioblastoma cells, which indicates that lysosome
inhibition may enhance proteasome degradation or endoplas-
mic reticulum-associated degradation in a compensatory way.
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Figure 4 VCP knockdown increased the radiation resistance of GBM cells. (a) Exponentially growing parent U251, U87, M059K, M059J cells or cells infected with control
lentiviruses or VCP shRNA lentiviruses were separately seeded in 10-cm dishes (400 cells per dish), clonogenic assays were performed following radiation treatment at the
indicated doses, and the survival fraction were normalised to control cells. (b) the Kaplan–Meier survival curve was made for orthotopic GBM mice in four groups (*Po0.05);
the radiation enhancement of survival time was calculated based on the formula: the radiation enhancement of survival time¼ the extended survival time/the survival
time without radiation treatment. (c) The average tumour size and the representative MR images in each group and representative VCP immunofluorescence images (red) in
xenografted glioblastoma sections. (d) Correlation analysis of VCP protein levels with patient survival, and the representative VCP immunohistochemistry images in paraffin
sections from glioblastoma patients. (e) Representative pictures from each group (Con: para-tumour tissue)
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Furthermore, although DNA-PK is thought to be a nucleolus
protein, our observation suggests that DNA-PK, or at least its
catalytic subunit, is also located in the cytoplasm,21 and that
VCP associated with it and regulated its degradation. The co-
IP experiment identified that both the N-terminal domain and
the D1 domain of the VCP protein could bind to DNA-PK,
which is consistent with the recent findings of co-IP and
biolayer interferometry experiments using a VIM peptide of
gp78;30 this conclusion was also partially consistent with
early data that showed that the rhodopsin (P23H) protein only
interacts with the p97ND1 domain, but not the isolated p97N
domain.25 However, the VCP ND2 domain exhibits no
detectable binding with DNA-PKcs, and the D1D2 domain
also weakens the binding affinity of the D1 domain with DNA-
PKcs. These results indicate that VCP association with the
target protein is affected by conformational changes, which
may be induced by ATP binding/hydrolysis or hierarchical
binding. Moreover, it was reported that one single amino-acid
substitution (R155H) at the interface between the N-terminal
domain and the adjacent AAA domain (D1) of VCP results
in a reduced affinity for ADP.31 Although the previous data
showed that VCP was phosphorylated by DNA-PK in
response to DNA damage, it is not clear whether this
phosphorylation of VCP affects its binding with DNA-PK or
regulates VCP activation.
In addition, biochemical and structural studies have
demonstrated that multiple cofactors recognised by VCP
(p97) contain the ubiquitin regulatory X (UBX) domain present
in the UBX protein family or the ubiquitin-like domain of
NPL4.30 In addition to the fact that VCP is phosphorylated at
Ser 784, DNA-PKcs also contains the VIM motif of ‘AAXXR’
(Figure 1a), which is conserved in mammals and is consistent
with the previous finding.30 Our data also showed that
DNA-PKcs is ubiquitinated and its degradation is ubiquitin-
proteasome-dependent; however, the specific ubiquitylated
site(s) of DNA-PKcs and its corresponding E3 ligase have
not been discovered yet and will be addressed in our
future studies.
DSB is a most lethal type of DNA damage; if the cell is
unable to fix this damage, the unrepaired DSBs may result in
cell death. As a central component of the NHEJ, DNA-PK
controls the process of DSB repair and maintains the stability
of the genome. Alterations in DNA-PK activities or amounts of
the DNA-PKcs protein will most likely change the sensitivity of
cells to genotoxic stress, such as radiation. It is well known
that DNA-PKcs-/- mice are hypersensitive to radiation and
undergo ATM- and p53-dependent apoptosis.32–34 However,
data from TCGA and our group suggest that there is no
significant difference in the DNA-PKcs protein levels between
normal glial tissue and GBM tumour tissue, although in some
cases, immunohistochemistry analysis showed that tumour
cells express more DNA-PKcs than adjacent normal tissue,35
which may be due to the tissue specificity.
To avoid potential side effects caused by DNA-PK
inhibitors, targeting DNA-PK regulatory proteins that are
upregulated in radiation-resistant glioblastoma cells is an
alternative strategy for radiosensitisation treatment. We
previously found that the protein phosphatase PP6 regulates
the radiation sensitivity of GBM cells through DNA-PK, and
that knocking down PP6c increases the survival time of mice;
moreover, PP6c was overexpressed in 44.7% (17 of
38 cases) of GBM patients.21,22,36,37,24
In this study, knocking down VCP not only caused the
accumulation of the DNA-PKcs protein, but it also elevated
the DNA-PK activity and promoted the efficiency of DNA
damage repair in GBM cells. Although VCP knockdown
affected 53BP1 recruitment into the DNA damage sites and
seemed to increase the radiation sensitivity of U2OS cells and
nematode,15,16 our data showed that the accumulation
of DNA-PK increased the efficiency of DNA damage repair
in GBM cells, which might be a result of p53-independent
pathways and a different cellular roles of VCP in different
types of cells.38 Our in vivo study confirmed that VCP
knockdown reduced the radiosensitivity and shortened the
survival time of mice in a GBM orthotopic model. The clinical
data also supported this conclusion. Therefore, the small
molecules that selectively target the VCP protein could
influence the radiation sensitivity by regulating DNA-PK protein
level. These observations suggest that DNA-PK regulatory
proteins are potential targets for radiosensitisation treatment.
Materials and Methods
Human subjects and tumour samples. The research protocol was
approved by the Institutional Review Board of the Shanghai Jiao Tong University
School of Medicine. A total of 38 GBM patients were recruited in the affiliated Renji
Hospital neurosurgical clinic and provided informed consent; patients with newly
diagnosed, histologically confirmed GBM (World Health Organisation grade IV
astrocytoma) were eligible for this study. These eligible patients received standard
radiotherapy (fractionated focal irradiation in daily fractions of 2 Gy given 5 days
per week for 6 weeks) without chemotherapy within 1 month after the surgery
for subtotal removal. The primary end point was patient’s death.
The orthotopic GBM mouse model. Congenitally athymic nude mice,
five to six weeks old (Charles River Laboratories, Wilmington, MA, USA), were
used in this study, which was approved by the Shanghai Jiao Tong University
Animal Care and Use Committee. Under deep isoflurane anaesthesia, mice were
placed in a small-animal stereotactic frame (David Kopf Instrument, Tujunga,
CA, USA). A sagittal incision was made to expose the cranium, and a bur hole
was made in the skull, 0.2 mm anterior and 1.8 mm lateral (right), from the bregma
using a small dental drill. At a depth of 3 mm from the brain surface, a 1 106
cells/5ml cell suspension was injected. Five minutes later, the needle was
removed and the hole was sealed with bone wax. The wound was sutured
immediately. The survival times of the mice were recorded. The intragroup
variation in length of survival, including the S.D. and 95% confidence interval
determinations, were analysed.
In vivo MRI imaging of tumour. GBM-bearing mice, with or without
radiation, were examined on day 9, 29 days post-tumour implantation to detect the
growth of the grafted tumour fragments. Tumour imaging was performed with a
small-animal coil on a high-field GE Signa 3-tesla clinical MR scanner (General
Electric, Waukesha, WI, USA), and images were obtained using a standard T1
protocol following an intraperitoneal injection of gadolinium (Gd-DTPA, 100ml/20
g, Bayer Inc., Pittsburgh, PA, USA) 10min before examination. In enhanced
scanning, the scanning parameters were: AxT1 FSE series: Scan plane: oblique;
FOV: 5.0; phase FOV: 0.60; slice thickness: 1.0 mm; spacing: 0.0 mm; Freq DIR:
R/L; Auto TR: 600, minimum TR: 60. The tumour sizes were measured and their
volumes were calculated with Function Analysis software according to the
following formula: (length x width2)/2. These results were subsequently analysed
using Image Pro Plus software (Media Cybernetics, Rockville, MD, USA).39
siRNA knockdown of VCP. Exponentially growing U87 or U251 cells were
infected with lentiviruses containing specific shRNA against VCP, shRNA
sequence: 50-CGCATTGTATCACAGTTGT-30 (sense); 50-ACAACTGTGATACAAT
GCG-30 (antisense). The preparation of lentiviruses was according to a previously
described protocol.21 A nonspecific siRNA (sequence: 50-AAAUCUUCGAGACAU
UCUGUU-30) was used as a control. The other siRNA oligonucleotides used in this
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study were purchased from Dharmacon (Fisher scientific, Pittsburgh, PA, USA)
and transfected into the cells using LipofectAMINE RNAiMAX (Invitrogen, Grand
Island, NY, USA) according to the manufacturer’s instructions.
Radiation treatment. Cells in culture were irradiated with an irradiator
(GE 3000) using a 137Cs source at a dose rate of 4.0 Gy per minute. Mice were
observed daily following tumour cell injection; 10 days after xenograft
transplantation, with the aid of GE HiSpeed CT, radiation was delivered accurately
to the brain tumours of mice, 2 Gy each time, by an ELEKTA Precise accelerator;
the body did not receive any radiation. The following radiation schedule,
established in preliminary studies, was used during the course of this study: 2 Gy
M-W-F for 1 week (6 Gy total administered over 7 days). All mice used for therapy
response evaluations were euthanised at the time of reaching a moribund
condition.
DNA-PK kinase assay. Exponentially growing cells were treated with 10 Gy
IR. After 30min, the nuclear extracts were prepared as previously described.21
Briefly, the cells were permeabilised and the nuclei were extracted in lysis buffer
containing 0.42M NaCl and 1.5 mM MgCl2. DNA-PK activity was analysed using a
DNA-PK activity assay kit40,41 according to the manufacturer’s instructions
(Promega Inc., Madison, WI, USA).
Immunoprecipitation. Exponentially growing U87 or U251 cells were
irradiated with 10 Gy IR, then harvested at indicated time points and lysed in
1ml of lysis buffer (0.5% (v/v) NP-40, 5mM EDTA, 2 mM EGTA, 20mM MOPS,
1mM PMSF, 20mM sodium pyrophosphate, 30mM sodium fluoride, 40mM
b-glycerophosphatase, 1 mM Na3VO3, and protease inhibitors) with caspase
inhibitor Z-VAD-FMK. Aliquots of 1 mg of total protein were mixed with 4 mg of
monoclonal anti-DNA-PKcs antibody at 4 1C overnight. The bound proteins were
recovered by binding to 25ml of protein-A agarose (Sigma, St. Louis, MO, USA).
The samples were separated by 7.5% SDS-PAGE gel electrophoresis and were
then transferred to nitrocellulose membranes. Proteins of interest were detected
with specific antibodies. Blots were scanned using an Odyssey infrared imaging
system (LI-COR, Lincoln, NE, USA), and proteins were quantitatively analysed
with the Odyssey software.
Comet assay. The comet assay was performed under neutral conditions
according to the procedures of Singh et al.42 with modifications by Klaude et al.43
The control U251 or the U251 cells with VCP siRNA were irradiated at doses of
10 Gy. After the radiation, the cells were allowed to repair for 30, 180 and 360min
or were harvested immediately (time 0¼ no repair), suspended in 1.0% low-
melting agarose dissolved in PBS, and layered onto microscope slides previously
covered with 0.5% normal melting point agarose. Cells were lysed at 37 1C
overnight in a buffer consisting of 2% Sarkosyl, 500mM EDTA, 0.5 mg/ml
protein K, pH 8.0. Next, the DNA was unwound and uncoiled in the electrophoresis
buffer that consisted of 90mM boric acid, 90mM TrisHCl and 2mM EDTA(pH
8.5) for 30min. Then, electrophoresis was carried out in the dark, and the cells
were stained with DAPI solution. The slides were examined with an Eclipse
fluorescence microscope. The comet tail moment was measured in 100 cells
randomly selected from each sample. Each experiment was repeated three times.
Clonogenic assay. The clonogenic assay was adapted from Franken et al.44
Briefly, the IR-treated and untreated cells were harvested and 400 cells per dish
were reseeded in a 100-mM dish at an appropriate density to obtain B50–100
colonies. Following 10–14 days of incubation, cells were fixed and stained with
crystal violet, and colonies containing at least 50 cells were scored.
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